A Phase 1a/b, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C137, an Antibody-Drug Conjugate Targeting FGFR2b, in Patients With Advanced Solid Tumors
Latest Information Update: 17 Dec 2024
Price :
$35 *
At a glance
- Drugs BG C 137 (Primary)
- Indications Gastrointestinal cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors BeiGene
- 12 Dec 2024 Status changed from not yet recruiting to recruiting.
- 08 Oct 2024 New trial record